Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919954 · ClinicalTrials.gov registry record · Phase 1
Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
A Phase 1 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04919954 is a Phase 1 study that has completed, run by Hartford Hospital. The registered enrollment target is 12 participants.
The verdict
NCT04919954, a Phase 1 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will determine the tissue penetration of a broad-spectrum orally bioavailable carbapenem, tebipenem pivoxil hydrobromide (SPR994) (Spero Therapeutics, Inc.), into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.
Interventions
- DRUG Tebipenem Pivoxil Hydrobromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2022-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919954
The ClinicalTrials.gov registry entry for NCT04919954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tebipenem Pivoxil Hydrobromide is the first listed.
NCT04919954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04919954 about?
NCT04919954 is a clinical study titled "Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis". This study will determine the tissue penetration of a broad-spectrum orally bioavailable carbapenem, tebipenem pivoxil hydrobromide (SPR994) (Spero Therapeutics, Inc.), into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will b...
What is the current status of trial NCT04919954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-07-01. Estimated completion is 2022-12-23.
What interventions are being tested in trial NCT04919954?
The interventions under investigation include: Tebipenem Pivoxil Hydrobromide (DRUG).
Who is sponsoring clinical trial NCT04919954?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.